← Back to Search

1 for Chronic Pain

Phase 2
Waitlist Available
Led By Christopher deCharms, PhD
Research Sponsored by Omneuron
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of the trial
Awards & highlights

Study Summary

The purpose of this study is to test a new investigational method for treatment of chronic pain using cognitive training guided by functional magnetic resonance imaging (fMRI).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of the trial
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of the trial for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measures of Pain Magnitude; McGill Pain Questionnaire; Visual Analogue Scale; Coping Strategies; Pain Catastrophizing Scale; Beck Depression Inventory; Treatment Outcome of Pain States; Increased control over brain activation measured using fMRI

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: 1Active Control1 Intervention
Participants will see their own brain activation.
Group II: 2Placebo Group1 Intervention
Participants will see simulated data that does not come from their own brains.

Find a Location

Logistics

Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Who is running the clinical trial?

OmneuronLead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,341 Previous Clinical Trials
649,958 Total Patients Enrolled
12 Trials studying Chronic Pain
1,541 Patients Enrolled for Chronic Pain
Christopher deCharms, PhDPrincipal InvestigatorOmneuron

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~8 spots leftby May 2025